Two Republican lawmakers on Thursday questioned the Federal Trade Commission’s (FTC) efforts to unwind life science company Illumina’s US$7.1 billion acquisition of Grail, alleging the regulator was not following a normal path in its work, reported Reuters.
Members of Congress Jim Jordan and Darrell Issa wrote in a letter to FTC Chair Lina Khan that agency actions related to the deal require congressional oversight, demanding documents related to the FTC’s work.
“The FTC’s approach to the Illumina-GRAIL merger departs from its typical enforcement process and raises questions about the Commission’s interference in the case,” the September 2 letter stated.
Among their complaints, the members of Congress alleged that the FTC filed for an injunction in federal court to give it time to litigate the case before the FTC’s own internal administrative court “to avoid speedily resolving novel legal issues under U.S. law in a forum – federal district court – where the FTC was more likely to lose.”
The FTC has argued that cancer test detection company Grail and its competitors rely on San Diego, California-based Illumina’s DNA sequencing technology. They alleged that Illumina’s purchase of Grail would give the company the “incentive and ability to foreclose downstream rivals.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Lawmaker Probes FTC and EU’s Role in Amazon’s Failed iRobot Acquisition
May 2, 2024 by
CPI
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Healthcare Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI